Literature DB >> 16432157

AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model.

I-Fen Chen1, Fu Ou-Yang, Jen-Yu Hung, Jaw-Ching Liu, Hongying Wang, Shao-Chun Wang, Ming-Feng Hou, Gabriel N Hortobagyi, Mien-Chie Hung.   

Abstract

IFN-inducible proteins are known to mediate IFN-directed antitumor effects. The human IFN-inducible protein absent in melanoma 2 (AIM2) gene encodes a 39-kDa protein, which contains a 200-amino-acid repeat as a signature of HIN-200 family (hematopoietic IFN-inducible nuclear proteins). Although AIM2 is known to inhibit fibroblast cell growth in vitro, its antitumor activity has not been shown. Here, we showed that AIM2 expression suppressed the proliferation and tumorigenicity of human breast cancer cells, and that AIM2 gene therapy inhibited mammary tumor growth in an orthotopic tumor model. We further showed that AIM2 significantly increased sub-G(1) phase cell population, indicating that AIM2 could induce tumor cell apoptosis. Moreover, AIM2 expression greatly suppressed nuclear factor-kappaB transcriptional activity and desensitized tumor necrosis factor-alpha-mediated nuclear factor-kappaB activation. Together, these results suggest that AIM2 associates with tumor suppression activity and may serve as a potential therapeutic gene for future development of AIM2-based gene therapy for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432157     DOI: 10.1158/1535-7163.MCT-05-0310

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  48 in total

Review 1.  AIM2 in health and disease: Inflammasome and beyond.

Authors:  Puja Kumari; Ashley J Russo; Sonia Shivcharan; Vijay A Rathinam
Journal:  Immunol Rev       Date:  2020-07-26       Impact factor: 12.988

Review 2.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 3.  Inflammasomes in Myeloid Cells: Warriors Within.

Authors:  Sushmita Jha; W June Brickey; Jenny Pan-Yun Ting
Journal:  Microbiol Spectr       Date:  2017-01

4.  Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense.

Authors:  Daeho So; Hyun-Woo Shin; Jiyoung Kim; Mingyu Lee; Jongyun Myeong; Yang-Sook Chun; Jong-Wan Park
Journal:  Oncogene       Date:  2018-05-29       Impact factor: 9.867

Review 5.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

6.  AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics.

Authors:  Miao Qi; Dan Dai; Jin Liu; Zhongqi Li; Panpan Liang; Yue Wang; Lu Cheng; Yihong Zhan; Zhifeng An; Yaoyao Song; Yana Yang; Xiaohui Yan; Hui Xiao; Huanjie Shao
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

Review 7.  Absent in melanoma 2 proteins in the development of cancer.

Authors:  Divaker Choubey
Journal:  Cell Mol Life Sci       Date:  2016-06-21       Impact factor: 9.261

Review 8.  Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity.

Authors:  Divaker Choubey; Xin Duan; Eric Dickerson; Larissa Ponomareva; Ravichandran Panchanathan; Hui Shen; Ratika Srivastava
Journal:  J Interferon Cytokine Res       Date:  2010-06       Impact factor: 2.607

9.  Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance.

Authors:  Zhenwei Gong; Xinyi Zhang; Kai Su; Ruihua Jiang; Zhe Sun; Wei Chen; Erick Forno; Eric S Goetzman; Jieru Wang; H Henry Dong; Partha Dutta; Radhika Muzumdar
Journal:  Diabetologia       Date:  2019-09-11       Impact factor: 10.122

10.  Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Authors:  Ke Zhang; Daniel Kagan; Wendy DuBois; Richard Robinson; Valery Bliskovsky; William C Vass; Shuling Zhang; Beverly A Mock
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.